Maze Therapeutics (NASDAQ:MAZE) Insider Phillips Courtney Sells 2,012 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Phillips Courtney sold 2,012 shares of the company’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $52,332.12. Following the completion of the sale, the insider owned 7,007 shares in the company, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

• On Wednesday, September 2nd, Phillips Courtney sold 1,981 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $52,437.07.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $26.21 on Friday. The business’s 50 day simple moving average is $28.69 and its 200 day simple moving average is $31.17. Maze Therapeutics, Inc. has a one year low of $14.27 and a one year high of $53.65. The stock has a market capitalization of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, research analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada lifted its position in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics in the second quarter valued at approximately $48,000. Finally, Russell Investments Group Ltd. grew its holdings in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the period.

Analyst Ratings Changes

Several research analysts have recently weighed in on MAZE shares. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Three research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Maze Therapeutics has an average rating of “Buy” and an average price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.